Table 1.
Subject characteristics
| Subject Characteristics | Frequency |
|---|---|
| Gender | |
| Male | 33 (66%) |
| Female | 17 (34%) |
| Age (Mean ± SD) | 30.60 ± 5.58 |
| BMI (kg/m2) (Mean ± SD) | 20.52 ± 2.40 |
| Smoking status | |
| No | 34 (68%) |
| Yes | 16 (32%) |
| Smoking duration (years), median (min-max) | 0 (0-20) |
| HBsAg Status | |
| Negatif | 50 (100%) |
| Reactif | 0 (0%) |
| Anti HCV Status | |
| Negatif | 49 (98%) |
| Reactif | 1 (2%) |
| TBC status | |
| Negatif | 42 (84%) |
| On treatment | 5 (10%) |
| End of treatment | 3 (6%) |
| Combination therapy | |
| TDF/3TC/EFV | 26 (52%) |
| AZT/3TC/NEV | 7 (14%) |
| TDF/3TC/NEV | 2 (4%) |
| AZT/3TC/EFV | 2 (4%) |
| AZT/3TC/aluvia | 1 (2%) |
| TDF/3TC/aluvia | 3 (6%) |
| Naif | 9 (18%) |
| ARV therapy duration (month), median (min-max) | 12 (0-120) |
| CD4/CD8 ratio | 0.275 (0.02- 1.39) |
| CD4/CD8 < 1 | 47 (94%) |
| CD4/CD8 ≥ 1 | 3 (6%) |
| CIMT (mm), median (min-max) | 0.75 (0.4-1.5) |